long-acting insulin degludec was as effective in lowering blood
sugar as Sanofi's top-selling Lantus and led to far
fewer incidents of potentially dangerous overnight hypoglycemia,
according to results from a late-stage study.
Friday, June 8, 2012
Novo insulin slashes noctural hypoglycemia in study
June 8 (Reuters) - Novo Nordisk's experimental
long-acting insulin degludec was as effective in lowering blood
sugar as Sanofi's top-selling Lantus and led to far
fewer incidents of potentially dangerous overnight hypoglycemia,
according to results from a late-stage study.
long-acting insulin degludec was as effective in lowering blood
sugar as Sanofi's top-selling Lantus and led to far
fewer incidents of potentially dangerous overnight hypoglycemia,
according to results from a late-stage study.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment